These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 28063331)

  • 21. Relationship between tumour size and response to neoadjuvant chemotherapy among breast cancer patients in a tertiary center in Nigeria.
    Samuel O; Olayide A; Ganiyu R; Olufemi H; Halimat A
    Malawi Med J; 2018 Mar; 30(1):13-16. PubMed ID: 29868153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
    Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
    Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
    Kümmel S; Paepke S; Huober J; Schem C; Untch M; Blohmer JU; Eiermann W; Gerber B; Hanusch C; Hilfrich J; Jackisch C; Schneeweiss A; Denkert C; Engels K; Klare P; Fasching PA; von Minckwitz G; Burchardi N; Loibl S
    Eur J Cancer; 2017 Oct; 84():1-8. PubMed ID: 28768217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological outcomes of HER2-positive non-metastatic breast cancer patients treated with neoadjuvant dual anti-HER2 therapy and taxane: An Australian experience.
    Choi JDW; Hughes TMD; Marx G; Rutovitz J; Hasovits C; Ngui NK
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):103-107. PubMed ID: 31218842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G; Loibl S; Maisch A; Untch M
    Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
    Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M
    Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
    Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
    Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
    Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
    Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
    Kern P; Kalisch A; von Minckwitz G; Pütter C; Kolberg HC; Pott D; Kurbacher C; Rezai M; Kimmig R
    J Chemother; 2016 Jun; 28(3):210-7. PubMed ID: 26239282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418).
    Kim H; Park W; Yu JI; Choi DH; Huh SJ; Kim YJ; Lee ES; Lee KS; Kang HS; Park IH; Shin KH; Kim K; Park KR; Kim YB; Ahn SJ; Lee JH; Kim JH; Chun M; Lee HS; Kim JS; Lee JY
    Oncotarget; 2017 Jan; 8(1):1796-1804. PubMed ID: 27793036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer.
    Ma X; Zhang X; Zhou X; Ren X; Ma X; Zhang W; Yang R; Song T; Liu Y
    Medicine (Baltimore); 2022 Oct; 101(40):e30892. PubMed ID: 36221359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy.
    Straver ME; Rutgers EJ; Oldenburg HS; Wesseling J; Linn SC; Russell NS; Vrancken Peeters MJ
    Am J Surg; 2009 Jul; 198(1):46-50. PubMed ID: 19095215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive Value of the Pattern of β-Catenin Expression for Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Elsamany S; Elemam O; Elmorsy S; Alzahrani A; Abbas MM
    Asian Pac J Cancer Prev; 2016; 17(8):4089-93. PubMed ID: 27644666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
    Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
    J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
    [No Abstract]   [Full Text] [Related]  

  • 39. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
    Marmé F; Lederer B; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Jackisch C; Kümmel S; Loibl S; Paepke S; Untch M; von Minckwitz G; Schneeweiss A
    Eur J Cancer; 2016 Jan; 53():65-74. PubMed ID: 26693900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait.
    Krishnan Y; Al Awadi S; Sreedharan PS; Sujith Nair S; Thuruthel S
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e30-7. PubMed ID: 23937427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.